⚠️ MFN Risk Management

MFN exposure is built through decisions you make every single day

By the time MFN pressure is visible in negotiations, strategic options are already constrained by prices set months or years earlier. GPI gives global pricing and market access teams the intelligence to take control before flexibility is lost.

Book a strategy call →

Control MFN risk from Day One — not after launch decisions have locked in your exposure

60+ pricing markets, 100+ IRP markets — validated proprietary data depth that competitors don't hold

Trusted by Top 10 global pharma — specialist pharmaceutical pricing intelligence since 2015

Trusted by leading pharmaceutical companies worldwide

Pfizer
AstraZeneca
Novo Nordisk
Moderna
Jazz Pharmaceuticals
Clarivate
Book a strategy call

Speak with GPI's MFN experts

A focused 30–45 minute conversation about your portfolio and where MFN risk sits. No commitment — we'll tailor the discussion to your specific situation.

1

Urgent portfolio assessment — rapid MFN exposure mapping for US policy response (MFN/Globe/Guard), difficult tenders, or sensitive upcoming launches.

2

GPI Pulse™ demonstration — see IRP tracking, launch sequence modelling, and portfolio risk dashboards tailored to your therapy area and markets.

3

Exploratory conversation — understand what's possible, or build an internal business case for systematic MFN management.

MFN Readiness Assessment tool
Free assessment
Not sure where to start? Take GPI's free MFN readiness assessment first.

Less than 10 minutes. Get an immediate picture of where your portfolio is most exposed before your call — so the conversation can focus on solutions, not diagnosis.

Start now — under 10 minutes →
Get in touch

Leave your details and we'll be in touch

A member of the GPI team will reach out to arrange a call that works for you.

Your data is handled in accordance with GPI's privacy policy. We will not share your details with third parties.

The MFN challenge

The same pattern plays out across every portfolio

MFN exposure isn't triggered by a policy announcement. It builds step by step — through commercially rational decisions that accumulate into portfolio-level constraints.

0
Month 0 — The launch decision
A commercially rational choice

Your team launches early in a progressive European market — fast access, real-world data, moderate pricing. Logical. But the price you negotiate is now a global reference point.

12
Month 12 — IRP basket entry
One local price, multiple global constraints

That launch price enters IRP baskets across Europe, Latin America, and Asia. Your early market now feeds into pricing calculations for Markets B, C, D, E, F, and G.

24
Month 24 — Higher-value market constraints
Payers reference your floor

You're negotiating in premium markets expecting strong pricing. Payers point to your earlier launch price — creating MFN-style pressure without any formal MFN clause.

36
Month 36 — Portfolio-level impact
Flexibility is already lost

Revenue gaps, margin erosion, constrained negotiations. What began as a tactical access decision has become a portfolio-level liability — and it's too late to adjust.

Why traditional approaches fail

Teams discover constraints when flexibility is already limited

Limited visibility

Pricing data fragments across regional databases and spreadsheets. Teams discover price points that create exposure only after they've entered reference systems.

Reactive timing

Quarterly cycles miss monthly IRP changes. Problems surface during negotiations — too late to adjust strategy.

Governance friction

Regional teams on different intelligence trigger "my data vs. your data" debates — slowing decisions when speed matters most.

Product-by-product firefighting

Without portfolio visibility, problems are addressed in isolation. Systemic risks go unnoticed while resources flow reactively to the most urgent negotiation.

GPI Pulse™

Three capabilities that shift teams from reactive to proactive

Teams using manual approaches discover MFN constraints during negotiations — when options are already limited. Teams using GPI Pulse™ model these scenarios during planning, when decisions can still be adjusted.

Global price tracking

Continuous visibility into where your lowest prices exist across 60+ markets — the net prices, reimbursed prices, and tender outcomes that actually enter IRP calculations. Know when your price enters a new reference basket before downstream markets are affected.

60+ pricing markets

IRP rules intelligence

The IRP Matrix across 100+ markets — basket composition, calculation methodologies, and update frequencies in detail. Reference chain mapping shows how price changes cascade both directly and indirectly, enabling accurate MFN exposure assessment before any commitment.

100+ IRP markets

Launch sequence insight

Historical launch sequence outcomes from hundreds of prior launches — showing which strategies maintained pricing integrity and which created unintended MFN exposure. Portfolio-level modelling quantifies revenue differences between sequences over 5+ years. Actual outcomes, not theoretical frameworks.

Actual outcomes, not models
Free strategic guide
Navigating MFN: Turn risk into predictable outcomes
A strategic guide for VP and Director-level global pricing & market access leaders.
Download free PDF →
Frequently asked questions

Questions about MFN risk and GPI

What exactly is MFN exposure in pharmaceutical pricing?

+
MFN exposure is created through the pricing and launch decisions your organisation makes every day. Once your lowest prices are established anywhere in the world — through tenders, reimbursement negotiations, or early access programmes — they become leverage points in every subsequent negotiation. Even in countries with no formal MFN agreement, payers use your lowest global price as a negotiating benchmark, constraining pricing flexibility across your entire portfolio.

Who is a GPI strategy call suitable for?

+
GPI's MFN strategy calls are for VP and Director-level global pricing and market access leaders — particularly those facing portfolio assessment needs driven by MFN, Globe, or Guard policy changes, teams planning launches in markets with complex IRP dynamics, and pricing leaders building a business case for systematic MFN management. The conversation is calibrated to your situation, whether urgent or longer-term.

What markets does GPI's intelligence cover?

+
GPI provides pricing and reimbursement intelligence across 60+ markets and IRP reference pricing intelligence across 100+ markets — including the EU5 (Germany, France, Italy, Spain, and the UK), the United States, APAC, the GCC, and the Nordics. Data covers list prices, net prices, reimbursed prices, and tender outcomes, with history from 2017 forward across all therapeutic areas.

Is there a free MFN readiness assessment?

+
Yes — GPI's free MFN readiness assessment is available at info.globalpricing.com/mfn-readiness-gpi. It takes under 10 minutes and gives pricing and market access teams a clear picture of where portfolio exposure is highest and which risks need priority attention. A useful starting point before booking a strategy call.

How does GPI differ from other pharmaceutical pricing providers?

+
Pharmaceutical pricing intelligence is GPI's sole focus — not a division of a diversified data business. GPI has invested over a decade building comprehensive pricing intelligence infrastructure across 60+ countries and 100+ IRP baskets, with history from 2017. Most competitors provide basic pricing databases without net price visibility, theoretical frameworks built on assumptions rather than validated data, or visualisation platforms that lack the data foundation to support confident MFN decisions.
Skip to content